Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Educates Professional Fiduciaries on the Benefits of Medical Marijuana

Nuvilex logo

SILVER SPRING, Md., April 28, 2014 (GLOBE NEWSWIRE) -- Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), a clinical stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, addressed conservators, guardians and trustees at the Professional Fiduciary Association of California (PFAC) Educational Conference in San Diego as part of the Medical Marijuana Education Session that occurred at the PFAC Educational Conference on April 25, 2014, where he discussed the medical benefits of the components of Cannabis (Marijuana).

Dr. Rabe's presentation detailed how Cannabis plant-based molecules, such as THC (tetrahydrocannabinol) and CBD (cannabidiol), provide broad medicinal benefits as their molecular structures are similar to "endocannabinoid" molecules. Endocannabinoid molecules occur naturally in the human body and regulate multiple systems. Dr. Rabe referred to research which documents the pain-relieving, anti-oxidative, neuroprotective and anti-cancer effects of THC, CBD and other cannabinoids that make them potentially useful in the treatment of a variety of medical conditions.

"It is gratifying to see the strong level of interest in medicinal Cannabis shown by professional organizations, such as PFAC, in order to serve the best interest of their clients," commented Dr. Rabe. "Our work at Medical Marijuana Sciences may further broaden patient options with respect to cannabinoid-based therapies, particularly in the treatment of deadly diseases like pancreatic and brain cancers. Now that the MMS Scientific Advisory Board has successfully defined our initial lines of investigation, we anticipate moving forward with formal preclinical research soon," he continued.

Dr. Rabe spoke about the future of a plant that has been used as a medicine for thousands of years, describing how it is Medical Marijuana Sciences' mission to develop cannabinoid-based treatments utilizing Nuvilex's Cell-in-a-Box® technology as a bio-sustainable platform in order to provide targeted cancer chemotherapy.

About Medical Marijuana Sciences:

Medical Marijuana Sciences, Inc. (MMS), a wholly owned subsidiary of Nuvilex, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, MMS will examine ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides MMS a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.

About Nuvilex:

Nuvilex, Inc. is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. Nuvilex is also involved in clinical trials related to other aspects of pancreatic and other forms of cancer.

Safe Harbor:

This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include Nuvilex's ability to continue as a going concern, delays in clinical trials or flaws or defects regarding its products, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex's intellectual property and Nuvilex's continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.

More information about Medical Marijuana Sciences and Nuvilex can be found at and It can also be obtained by contacting Investor Relations and Media Contacts.

CONTACT: Investor Relations Contacts: Marlin Molinaro Marmel Communications, LLC Ph: 702.434.8692 Dillon Heins CorProminence, LLC Ph: 218.839.9051 Media Contact: Jules Abraham JQA Partners, LLC Ph: 917.885.7378

Source:Nuvilex, Inc.